Chronic progressive polyneuropathy has been reported in 8% of patients with Waldenstrom' s macroglobulinaemia,' 39% of those with multiple myeloma,2 and in many patients with monoclonal immunoglobulins (plasma cell dyscrasias) without other evidence of a malignant disease.36 Several observations suggest that the monoclonal antibody found in these patients may cause the neuropathy:
(1) monoclonal antibody may be demonstrated in the sural nerve biopsy,78 (2) some of these monoclonal immunoglobulins have a cross-reacting idiotype suggesting recognition of a common antigenic determinant,9 (3) the monoclonal antibody can be absorbed from the serum by incubation with peripheral nerve components,' "1 (4) a neuropathy in mice can be produced by passive transfer of these monoclonal antibodies,'2 and (5) suppression of the plasma cell dyscrasia with chlorambucil, steroids, or radiotherapy has been accompanied by improvement of the neuropathy. '3-" As the dosage of prednisone was slowly decreased to 50 mg every other day, the neuropathy progressed. By April 1979, he required short leg braces to walk. The gastrocnemius and anterior tibialis muscles were too weak to work against gravity. Deep tendon reflexes were absent, and there was decreased sensation to pin and vibration below the elbows and knees. Plasma exchanges were begun daily for 5 days. Two weeks later the anterior tibialis muscle was able to flex the ankle against gravity. This activity remained stable until 5 weeks after plasma exchange when the distal leg muscles were no longer functional against gravity. Regular plasma exchange for 5 days every 4-5 weeks was resumed, again with improvement in the strength of the anterior tibialis muscle within 2 weeks later.
Over the subsequent 2 years, the plasma exchanges were to climb stairs. There was no evident muscle weakness. Impaired sensation was now present below the mid-palms and ankles with impaired proprioception at the toes. After 2 more weekly treatments of exchanges, the procedures were stopped and 20 mg per day of prednisone added. Ten days later the paraesthesiae had worsened. Sixteen days after stopping plasma exchanges, despite melphalan and prednisone the sensory impairment had progressed to the knees and mid-forearm, along with recurrence of weakness of the anterior tibialis muscle and small muscles of the hands. The IgG cryoglobulin was now evident. Plasma exchange was restarted. The sensory and motor findings improved, but proprioception remained impaired below the ankles. She is continuing plasma exchange every 2 weeks, 34 months after the onset of therapy. If the plasma exchanges are delayed to 3 week intervals, the muscle weakness progresses along with decreasing sensation. Case 7 The patient has previously been reported.6 Despite chlorambucil therapy, the neuropathy progressed between February and April with the loss of wrist extensor function. Plasma exchanges were begun. Two weeks after the initial plasma exchange, he was able to hold the wrists against gravity. A week later, the wrists could be extended against gravity. The plasma exchanges were interrupted for 16 days and the extensor activity of the wrists disappeared. With resumption of plasma exchanges the ability to extend the wrists against gravity returned within one week. The plasma exchanges were continued weekly for 3 months with return of full wrist extensor function and function of the anterior tibialis muscles to the extent he no longer required ankle braces. The plasma exchanges were discontinued after 3 months without a rebound of the monoclonal IgM due to effects of 6 months of chlorambucil therapy. The IgM spike continues to be suppressed and the muscle strength has improved to the extent that he is able to perform woodworking projects. There is still significant atrophy of the small muscles of the hands 3 years after the IgM spike has been eliminated. Cases 4 months after the onset of plasma exchange therapy. In the other cases, there was no change in the nerve conduction studies by the completion of the plasma exchange trial (1 to 3 months) .
The effectiveness of plasma exchanges appeared to be independent of concomitant chemotherapy. As can be seen from the report of Case 1, disease progression occurred while taking prednisone, but the prednisone could be tapered and stopped after the plasma exchanges were begun with continuing clinical improvement. In Case 2, six weeks after the onset of chemotherapy and plasma exchanges there was marked clinical improvement and plasma exchanges were discontinued. The IgG cryoglobulin reappeared and despite the addition of prednisone, the paraesthesiae and weakness progressed. In Case 7, progressive paralysis of the extensors of the wrists developed during the first 2 months of chlorambucil therapy. The extensors of the wrists functioned weakly one week after starting plasma exchanges. When the plasma exchanges were interrupted for 2 weeks the IgM returned to 88% of the pre-pheresis level with loss of activity of the wrists. Wrist extensor activity recovered with resumption of plasma exchanges. Plasma exchange in Case 8 was not begun until after 4 months of slow progression of the sensory neuropathy on chlorambucil alone." All patients who demonstrated clinical improvement in the neuropathy did so within 2 weeks of onset of plasma exchange.
There was an apparent relationship between the degree of suppression of the monoclonal immunoglobulin and clinical response. Five of the six patients who improved after plasma exchange had a 64% or greater decrease in the monoclonal immunoglobulin. In Case 2 the cryoglobulin disappeared within 3 days of the first plasma exchange and it did not recur while on plasma exchange therapy. The effectiveness of plasmapheresis is depicted in the figure. For a monoclonal IgM, the antibody titre was decreased by up to 70% at 24 hours after one plasma exchange but returned to pre-treatment levels within 3 weeks (fig, Case 7,  10 ). An IgG antibody was decreased by 40% at 24 hours after plasma exchange (fig, Case 1) . After plasma exchange that the plasma exchange could be discontinued with continuing stabilisation or improvement in the neuropathy. This required at least 2 months of alkylating agent therapy.
Discussion
Progressive polyneuropathy associated with a plasma cell dyscrasia is not one entity but represents many different mechanisms of peripheral nerve injury. While it is presumed that the monoclonal antibody is capable of binding to a nerve component, this has only been demonstrated in three of the 10 patients in this study-Cases 7,10 9," and 10." Of these three patients, the IgM of Case 7 reacted with MAG and was associated with a demyelinating polyneuropathy, while in Cases 9 and 10 the IgM reacted with chondroitin sulphate and was associated with an axonal polyneuropathy. The other cases are being evaluated to see if the monoclonal antibody binds to other nerve components. It is likely that the nerve component to which the antibody binds, the degree of neural injury, and the kinetics of the class of antibody involved in this reaction are all important in the manifestations of the neuropathy and its potential for recovery.
If the antibody activity is related to the progressive neuropathy, plasma exchange should be a 
